SAM
GPCR icon

SEB Asset Management’s Structure Therapeutics GPCR Stock Holding History

SEB Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2M Hold
245,043
– – 0.05% 296
2026
Q1 		$11.8M Buy
+245,043
New +$16.8M 0.05% 289

Other funds holding GPCR

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

SEB Asset Management's GPCR Position: Q2 2026 in Review

SEB Asset Management held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 245,043 shares worth $13.2M. The position accounts for 0.05% of the portfolio, ranked #296.

SEB Asset Management first reported a position in GPCR in Q1 2026 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • SEB Asset Management held 245,043 shares of Structure Therapeutics worth $13.2M as of Q2 2026.
  • SEB Asset Management left its Structure Therapeutics share count unchanged in Q2 2026.
  • Structure Therapeutics made up 0.05% of SEB Asset Management's portfolio in Q2 2026, its #296 holding.
  • SEB Asset Management first reported a position in Structure Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.